Design of de novo peptides and electrophysiological testing for voltage-gated sodium channel 1.7 inhibition related to chronic pain treatment
与慢性疼痛治疗相关的电压门控钠通道 1.7 抑制的从头肽设计和电生理学测试
基本信息
- 批准号:10660928
- 负责人:
- 金额:$ 4.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-03 至 2024-12-02
- 项目状态:已结题
- 来源:
- 关键词:Action PotentialsAdultAffinityAmericanBenchmarkingBindingBiological AssayBiological ProductsBiological Response Modifier TherapyCardiacCellsChargeClinicalCommunicationComplexComputational ScienceCryoelectron MicroscopyDataDevelopmentDisulfidesDrug DesignElectrophysiology (science)FamilyGeneticHeart ArrestHumanHuman GeneticsHydrophobicityIndustry CollaborationIntegral Membrane ProteinInvestigationIon ChannelKnowledgeLearningLibrariesManualsMethodologyMethodsModificationMutagenesisMutateNeurobiologyNeurosciencesNeurotoxinsNociceptionPain managementParalysedPathologyPeptidesPeripheral Nervous SystemPeruvianPharmaceutical PreparationsPositioning AttributeProtein EngineeringProteinsPublishingResearchResolutionSafetyScorpionsSeizuresSideSodiumSodium ChannelSoftware DesignSpidersStructureTestingTherapeuticTimeToxinTrainingTranslational ResearchValidationVariantWorkacademic preparationaddiction liabilitycareerchemical stabilitychronic painchronic pain managementclinical efficacycytokinedesigndrug candidatedrug discoveryeffective therapyexperienceexperimental studyfallsimprovedknowledgebasemimeticsnanomolarneuronal excitabilitynon-opioid analgesicnovelpain signalpatch clamppeptidomimeticspre-clinicalprescription opioidpreservationprotein structure predictionrational designscreeningskeletalskillssmall moleculestructural imagingtargeted treatmentthermostabilityvalidation studiesvirtual screeningvoltage
项目摘要
Project Summary/Abstract
Current drug discovery efforts for non-addictive, chronic pain management are targeting human voltage-gated
sodium (hNaV) channels: pore-forming transmembrane proteins that evoke the fast action potential in excitable
neuronal, cardiac, and skeletal cells. Genetic and preclinical target validation studies have identified hNaV1.7,
hNaV1.8, hNaV1.9 channel subtypes as key proteins in pain signaling with emphasis on hNaV1.7 for its
predominant expression in the peripheral nervous system. Attempts at selectively targeting hNaV1.7 with pre-
clinical small-molecule drugs fall short due to non-selective binding to other hNaV channel subtypes and other
ion channel families; non-selective binding can lead to cardiac arrest, paralysis and seizure. Peptide toxins
originating from tarantula, spider, and scorpion have been identified as potent hNaV-inhibiting biologics.
Notably, Protoxin-II, the neurotoxin from the Peruvian green velvet tarantula, has approximately 1 nM half-
maximal inhibitory concentration (IC50) to hNav1.7. However, these peptide toxins also have non-selective
binding to hNav1.7. With recent cryo-EM structural images of Protoxin-II bound to voltage-sensing domain II of
hNaV1.7, it is now possible to design peptides mimicking Protoxin-II that are selective to hNaV1.7. Advances in
de novo protein design methods using Rosetta – a protein structure prediction and design software suite –
enable a new avenue of drug design and virtual screening prior to experimental validation. Thus, the project
aims to create new peptides inspired from Protoxin-II to selectively target hNaV1.7. The methodology designs
new peptide topologies that incorporate the Protoxin-II motif structurally shown to bind to hNaV1.7. The
peptides are further optimized to bind to residues unique to hNaV1.7: residues that are not targeted by natural
peptide toxins. Upon synthesis of candidate peptides, they will be validated to selectively target hNaV1.7 using
whole-cell patch-clamp electrophysiology. The results will improve our mechanistic understanding needed for
selective, yet potent hNaV1.7 inhibition. Further, this research will be the first attempt at using a combination of
Rosetta de novo protein design methods to create unique peptides selective for hNaV1.7. The applicant upon
completion of this project will have a refined expertise of computational protein design methods and receive
training in electrophysiology for the first time. Throughout this project, the sponsor and co-sponsor will
implement a training plan to strengthen the applicant’s knowledge of neuroscience and drug discovery, while
broadening their collaborative network, and sharpening their scientific communication skills. This plan is
tailored such that the applicant is prepared for an academic career designing peptide biologics for the
treatment and investigation of ion channel pathologies.
项目摘要/摘要
目前用于非上瘾、慢性疼痛治疗的药物发现工作针对的是人类的电压门控
钠(HNaV)通道:在可兴奋状态下激发快速动作电位的成孔跨膜蛋白
神经细胞、心脏细胞和骨骼细胞。遗传学和临床前靶点验证研究已经确定了hNaV1.7,
HNaV1.8、hNaV1.9通道亚型作为疼痛信号的关键蛋白,重点是hNaV1.7在其
在外周神经系统中的主要表达。尝试选择性地将hNaV1.7作为靶点
临床小分子药物由于非选择性结合其他hNaV通道亚型和其他
离子通道家族;非选择性结合可导致心脏骤停、瘫痪和癫痫。多肽毒素
来源于狼蛛、蜘蛛和蝎子已被确定为有效的抑制hNaV的生物制品。
值得注意的是,原毒素-II,来自秘鲁绿色天鹅绒狼蛛的神经毒素,大约有1 NM的一半-
对hNav1.7的最大抑菌浓度(IC50)。然而,这些多肽毒素也具有非选择性
绑定到hNav1.7。结合最新的冷冻-EM结构图像,原毒素-II结合到电压敏感结构域II
HNaV1.7之后,现在可以设计对hNaV1.7具有选择性的模拟原毒素-II的多肽。最新进展
使用Rosetta的从头蛋白质设计方法-一套蛋白质结构预测和设计软件-
在实验验证之前启用药物设计和虚拟筛选的新途径。因此,该项目
目的是创造受原毒素-II启发的新多肽,以选择性地靶向hNaV1.7。方法论设计
结构上显示与hNaV1.7结合的结合了原毒素-II基序的新的多肽拓扑。这个
进一步优化多肽以结合hNaV1.7独有的残基:天然未靶向的残基
多肽毒素。在合成候选多肽后,它们将被验证为选择性靶向hNaV1.7
全细胞膜片钳电生理学。结果将提高我们对以下方面所需的机械理解
选择性的,但有效的hNaV1.7抑制。此外,这项研究将是首次尝试使用
Rosetta de novo蛋白设计方法创建对hNaV1.7具有选择性的独特多肽。申请人须于
完成这个项目将拥有精湛的计算蛋白质设计方法的专业知识并获得
第一次接受电生理学培训。在整个项目中,赞助商和共同赞助商将
实施培训计划,以加强申请者的神经科学和药物发现知识,同时
拓宽他们的合作网络,提高他们的科学交流技能。这个计划是
量身定做,使申请人为学术生涯做好准备,为设计多肽生物制品
离子通道病理的治疗和研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brandon John Harris其他文献
Brandon John Harris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brandon John Harris', 18)}}的其他基金
Design of de novo peptides and electrophysiological testing for voltage-gated sodium channel 1.7 inhibition related to chronic pain treatment
与慢性疼痛治疗相关的电压门控钠通道 1.7 抑制的从头肽设计和电生理学测试
- 批准号:
10389511 - 财政年份:2022
- 资助金额:
$ 4.04万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 4.04万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)